Medications to Avoid in Autoimmune Hemolytic Anemia

High-Priority Drug Avoidance

• The American College of Physicians recommends that Fludarabine is contraindicated in patients with active AIHA or a history of AIHA 1, 2
• If AIHA develops during fludarabine treatment, the drug must be immediately discontinued and permanently avoided, as recommended by the National Comprehensive Cancer Network 1, 2
• The National Comprehensive Cancer Network warns that fludarabine can cause life-threatening autoimmune hemolytic anemia, and its use should be avoided in patients with AIHA 1, 2
• Cilostazol and other antiplatelet agents should be avoided due to risk of exacerbating hemolysis, according to Praxis Medical Insights 3, 4
• If antiplatelet therapy is absolutely necessary for cardiovascular indications, the AIHA must first be aggressively treated with corticosteroids, as recommended by Praxis Medical Insights 4
• Hemoglobin, reticulocyte count, and bilirubin must be monitored closely if antiplatelet agents cannot be avoided, as suggested by Praxis Medical Insights 4

Common Drug-Induced Hemolytic Anemia Triggers

• Ciprofloxacin should be avoided in patients with AIHA due to risk of exacerbating hemolysis, according to the Journal of Clinical Oncology 5, 6
• Other fluoroquinolones should also be avoided when alternative antibiotics are available, as recommended by the Journal of Clinical Oncology 5, 6
• Penicillins and penicillin derivatives can cause drug-induced immune hemolytic anemia and should be used with caution, according to the Journal of Clinical Oncology 5, 6
• Rifampin can cause hemolysis and should be avoided in patients with AIHA, as warned by the Journal of Clinical Oncology 5, 6

Critical Clinical Pitfalls

• When a patient with AIHA presents with worsening hemolysis, immediately review all medications for potential drug-induced causes, as recommended by the Journal of Clinical Oncology 5, 6
• Initiate corticosteroids for moderate to severe hemolysis, as suggested by Praxis Medical Insights 3
• Provide supportive care including folic acid 1 mg daily, as recommended by the Journal of Clinical Oncology and Praxis Medical Insights 6, 3
• Consider RBC transfusion only to maintain hemoglobin 7-8 g/dL or relieve symptoms, as suggested by the Journal of Clinical Oncology 6

Monitoring Requirements

• Monitor hemoglobin weekly during treatment if any potentially hemolytic drug cannot be avoided, as recommended by Praxis Medical Insights 3
• Check reticulocyte count, haptoglobin, and LDH regularly if any potentially hemolytic drug cannot be avoided, as suggested by the Journal of Clinical Oncology and Praxis Medical Insights 5, 3